Eli Lilly and Company (LLY)
Why Eli Lilly Topped the Market on Tuesday
The pharmaceutical giant has been investigating its Zepbound/Mounjaro drug for various indications. It performed very well in its latest diabetes and weight loss study.
Eli Lilly: Tirzepatide's Winning Streak Continues
Eli Lilly's key growth product tirzepatide (Mounjaro/Zepbound) continues to deliver on both fronts. Increased supply visibility led to a $3 billion increase in the full-year total revenue guidance range. After strong Q2 results, Eli Lilly reported positive long-term data from the SURMOUNT-1 trial, showing long-term treatment with tirzepatide significantly reduced the risk of onset of type 2 diabetes.
Why Eli Lilly Stock Jumped to a Record High on Tuesday
Eli Lilly (LLY) stock jumped to a record high on Tuesday after clinical trial results showed tirzepatide—the active ingredient in Lilly's injectable weight-loss drug Zepbound and diabetes treatment Mounjaro—lowered patients' risk of developing type 2 diabetes by 94%.
Preliminary Late-Stage Study Boosts Eli Lilly Stock
Eli Lilly And Co (NYSE:LLY) announced today preliminary results from a late-stage study indicated the main ingredients Zepbound and Mounjaro of weight-loss drug tirzepatide reduced the risk of progression to type 2 diabetes by 94%.
Eli Lilly's weight-loss pill shows 94% reduction in diabetes risk: Is a $1 trillion valuation next?
Eli Lilly & Co (NYSE: LLY) has made a groundbreaking revelation that its weight-loss drug, Tirzepatide, reduces the risk of developing type 2 diabetes by an astonishing 94% in overweight adults with pre-diabetes.
Eli Lilly's Mounjaro cuts risk of developing Type 2 diabetes, study finds
Eli Lilly & Co.'s stock LLY gained more than 2% premarket on Tuesday after the drugmaker said that tirzepatide, marketed as the diabetes drug Mounjaro and weight-loss treatment Zepbound, sharply cut patients' risk of developing Type 2 diabetes in a late-stage trial.
Eli Lilly says weight-loss drug cut diabetes risk by 94% in trial
Eli Lilly said on Tuesday its weight loss drug cut the risk of developing diabetes by 94% in patients with pre-diabetes or those who were obese or overweight in a long-term study.
Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
Eli Lilly's weight loss drug reduced the risk of developing Type 2 diabetes by 94% in obese or overweight adults with pre-diabetes compared to a placebo, according to initial results from a long-term study. The late-stage trial on tirzepatide also found that patients experienced sustained weight loss over the roughly three-year treatment period.
Three Biotech Stocks to Buy for the "Golden Age of Medicine"
A year ago, medical experts and Nobel Laureates interviewed by The New York Times proclaimed "a Golden Age of Medicine" is here.
Prediction: These 2 Unstoppable Pharma Stocks Will Continue to Soar Through 2025 and Beyond
Novo Nordisk and Eli Lilly won't be constrained by manufacturing too much longer. That means they'll sell more of their in-demand drugs.
Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived
Last November, Eli Lilly received FDA approval for obesity drug Zepbound. In the second quarter, Zepbound generated over $1.2 billion in revenue!
Prediction: This Hypergrowth Company Could Be the Next Trillion-Dollar Stock
Eli Lilly is one of a few corporations close to hitting the $1 trillion mark. Despite a rich-looking valuation, the company should continue delivering strong returns.
